BACKGROUND: Studies in women indicate that some sexually transmitted infections promote human papillomavirus (HPV) persistence and carcinogenesis. Little is known about this association in men; therefore, we assessed whether Chlamydia trachomatis (CT) infection and herpes simplex virus type 2 (HSV-2) serostatus are associated with genital HPV prevalence, an early event in HPV-related pathogenesis. METHODS: Genital exfoliated cells, first-void urine, and blood from 3971 men recruited in the United States, Mexico, and Brazil were tested for HPV, CT, and HSV-2 antibodies, respectively. Multivariable logistic regression was used to assess the association of CT infection and HSV-2 serostatus with 4 HPV outcomes (any, oncogenic, nononcogenic only, and multiple infections). RESULTS: A total of 64 (1.6%) men were CT positive, and 811 (20.4%) men were HSV-2 seropositive. After adjustment for potential confounders, CT was associated with any HPV (adjusted odds ratio [aOR], 2.19; 95% confidence interval [CI], 1.13-4.24), oncogenic HPV (aOR, 3.10; 95% CI, 1.53-6.28), and multiple HPV (aOR, 3.43; 95% CI, 1.69-6.95) prevalence. Herpes simplex virus type 2 serostatus was associated with any HPV (aOR, 1.25; 95% CI, 1.02-1.52), nononcogenic HPV only (aOR, 1.38; 95% CI, 1.08-1.75), and multiple HPV (aOR, 1.33; 95% CI, 1.06-1.68) prevalence. In analyses stratified by sexual behavior, CT infection was significantly associated with HPV detection among men reporting 2 or more recent sexual partners, whereas HSV-2 serostatus was significantly associated with HPV detection in men reporting 0 to 5 lifetime sexual partners. CONCLUSION: In this population, CT infection and HSV-2 serostatus were associated with prevalent genital HPV infection. Future prospective studies should investigate whether these infections influence HPV acquisition and/or persistence.
BACKGROUND: Studies in women indicate that some sexually transmitted infections promote human papillomavirus (HPV) persistence and carcinogenesis. Little is known about this association in men; therefore, we assessed whether Chlamydia trachomatis (CT) infection and herpes simplex virus type 2 (HSV-2) serostatus are associated with genital HPV prevalence, an early event in HPV-related pathogenesis. METHODS: Genital exfoliated cells, first-void urine, and blood from 3971 men recruited in the United States, Mexico, and Brazil were tested for HPV, CT, and HSV-2 antibodies, respectively. Multivariable logistic regression was used to assess the association of CTinfection and HSV-2 serostatus with 4 HPV outcomes (any, oncogenic, nononcogenic only, and multiple infections). RESULTS: A total of 64 (1.6%) men were CT positive, and 811 (20.4%) men were HSV-2 seropositive. After adjustment for potential confounders, CT was associated with any HPV (adjusted odds ratio [aOR], 2.19; 95% confidence interval [CI], 1.13-4.24), oncogenic HPV (aOR, 3.10; 95% CI, 1.53-6.28), and multiple HPV (aOR, 3.43; 95% CI, 1.69-6.95) prevalence. Herpes simplex virus type 2 serostatus was associated with any HPV (aOR, 1.25; 95% CI, 1.02-1.52), nononcogenic HPV only (aOR, 1.38; 95% CI, 1.08-1.75), and multiple HPV (aOR, 1.33; 95% CI, 1.06-1.68) prevalence. In analyses stratified by sexual behavior, CTinfection was significantly associated with HPV detection among men reporting 2 or more recent sexual partners, whereas HSV-2 serostatus was significantly associated with HPV detection in men reporting 0 to 5 lifetime sexual partners. CONCLUSION: In this population, CTinfection and HSV-2 serostatus were associated with prevalent genital HPV infection. Future prospective studies should investigate whether these infections influence HPV acquisition and/or persistence.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk Journal: J Natl Cancer Inst Date: 2010-11-23 Impact factor: 13.506
Authors: Anna R Giuliano; Ji-Hyun Lee; William Fulp; Luisa L Villa; Eduardo Lazcano; Mary R Papenfuss; Martha Abrahamsen; Jorge Salmeron; Gabriella M Anic; Dana E Rollison; Danelle Smith Journal: Lancet Date: 2011-02-28 Impact factor: 79.321
Authors: Soyeon Kim; Jean Marie Arduino; Christine C Roberts; Mark Marsico; Kai-Li Liaw; Finn Egil Skjeldestad Journal: Sex Transm Dis Date: 2011-07 Impact factor: 2.830
Authors: Jennifer S Smith; Danielle M Backes; Michael G Hudgens; Robert C Bailey; Giovanni Veronesi; Martijn Bogaarts; Kawango Agot; J O Ndinya-Achola; Ian Maclean; Walter Agingu; Chris J L M Meijer; Stephen Moses; Peter J F Snijders Journal: Int J Cancer Date: 2010-01-15 Impact factor: 7.396
Authors: Anna R Giuliano; Eduardo Lazcano; Luisa Lina Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary Papenfuss; Martha Abrahamsen; Maria Luiza Baggio; Roberto Silva; Manuel Quiterio Journal: Int J Cancer Date: 2009-03-15 Impact factor: 7.396
Authors: Matti Lehtinen; Kevin A Ault; Erika Lyytikainen; Joakim Dillner; Suzanne M Garland; Daron G Ferris; Laura A Koutsky; Heather L Sings; Shuang Lu; Richard M Haupt; Jorma Paavonen Journal: Sex Transm Infect Date: 2011-04-06 Impact factor: 3.519
Authors: Keely Cheslack-Postava; Alan S Brown; Roshan Chudal; Auli Suominen; Jukka Huttunen; Helja-Marja Surcel; Andre Sourander Journal: Schizophr Res Date: 2015-05-26 Impact factor: 4.939
Authors: Maira A Castañeda-Avila; Erick Suárez-Pérez; Raúl Bernabe-Dones; Elizabeth R Unger; Gitika Panicker; Ana P Ortiz Journal: P R Health Sci J Date: 2020-03 Impact factor: 0.705
Authors: Michele D Picard; Jean-Luc Bodmer; Todd M Gierahn; Alexander Lee; Jessica Price; Kenya Cohane; Veronica Clemens; Victoria L DeVault; Galina Gurok; Robert Kohberger; Darren E Higgins; George R Siber; Jessica Baker Flechtner; William M Geisler Journal: Clin Vaccine Immunol Date: 2015-10-07
Authors: Shams Rahman; Deanna Wathington; Tim Waterboer; Michael Pawlita; Luisa L Villa; Eduardo Lazcano-Ponce; Martina Willhauck-Fleckenstein; Nicole Brenner; Anna R Giuliano Journal: PLoS One Date: 2021-06-22 Impact factor: 3.240
Authors: Staci L Sudenga; Sarah C Lotspeich; Alan G Nyitray; Bradley Sirak; Bryan E Shepherd; Jane Messina; Karen A Sereday; Roberto Carvalho Silva; Martha Abrahamsen; Maria Luiza Baggio; Manuel Quiterio; Eduardo Lazcano-Ponce; Luisa Villa; Anna R Giuliano Journal: Sex Transm Dis Date: 2022-01-01 Impact factor: 3.868